Blue Mint Pharmacy
Outcome
DEA issued Order to Show Cause and Immediate Suspension July 26, 2022, for filling controlled substance prescriptions with unresolved red flags; DEA registration No. FB4121327 revoked, order published November 2, 2023.
Details
Blue Mint Pharmacy — DEA Immediate Suspension and Revocation (2022–2023)
Outcome: DEA revoked Blue Mint Pharmacy's DEA Certificate of Registration No. FB4121327, published November 2, 2023, after issuing an Order to Show Cause and Immediate Suspension of Registration on July 26, 2022, for repeatedly filling controlled substance prescriptions without resolving numerous and blatant red flags of abuse and diversion.
On July 26, 2022, the Drug Enforcement Administration issued an Order to Show Cause and Immediate Suspension of Registration (OSC/ISO) to Blue Mint Pharmacy of Houston, Texas. DEA alleged the pharmacy had repeatedly filled prescriptions for controlled substances for multiple patients without adhering to Texas' operational standards for pharmacists and without addressing or resolving numerous red flags of abuse or diversion.
DEA's expert analysis reviewed Prescription Monitoring Program (PMP) data from approximately February 1, 2021, through March 31, 2022, along with patient profiles and copies of controlled substance prescriptions. The analysis found a recurring pattern of certain combinations of controlled substances with the same dosage and in large quantities to various patients, often paid for in cash rather than through insurance. This pattern was consistent with diversion activity and pharmacy-level complicity.
The expert concluded that the pharmacy's pharmacists were failing to engage in the required verification process before dispensing. Under Texas standard of care, a pharmacist who does not believe a prescription is for a legitimate medical purpose must refuse to fill it. Blue Mint's pattern demonstrated a systemic failure to apply this standard. The DEA signed the final Decision and Order on October 25, 2023, under Administrator Anne Milgram.
Primary Source: Blue Mint Pharmacy; Decision and Order (Fed. Reg. Nov. 2, 2023)
How Crucible Prevents This
DEA's expert found Blue Mint's pharmacists were repeatedly filling cash prescriptions for the same drug combinations in large quantities without engaging in required verification. A Crucible-enforced dispensing checklist would have flagged the recurring combination patterns as mandatory escalation triggers, creating an audit trail that either forces resolution or halts dispensing.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works